Viking Therapeutics Soars 8.61% on $230M Volume Surge to Rank 483rd in Trading Activity

On October 6, 2025, Viking Therapeutics (VKTX) surged 8.61% with a trading volume of $0.23 billion, marking a 47.54% increase from the previous day. The stock ranked 483rd in trading activity among listed equities, indicating heightened investor interest in the biopharmaceutical company’s recent developments.

Analysts noted that the sharp volume spike coincided with a strategic focus on advancing VK279, Viking’s lead candidate for metabolic disorders. Recent clinical data highlighted improved efficacy in Phase 2 trials, reinforcing the company’s pipeline potential. However, the absence of near-term regulatory milestones suggests market optimism is primarily driven by speculative positioning rather than immediate commercialization prospects.

For cross-sectional strategy backtesting, key parameters require clarification: defining the market universe (e.g., S&P 1500 vs. broad U.S. equities), weighting methodology (equal vs. volume-cap weighted), and execution timing (close-to-close vs. open-to-close). Transaction cost assumptions and data sources also remain pending. Once finalized, a daily-rebalanced strategy from January 3, 2022, to October 6, 2025, will generate performance metrics, including cumulative returns and risk-adjusted ratios.